このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

マスト摘出症症候群の慢性神経障害性疼痛のためのセラタス平面ブロック(SPB)対カプサイシン対ボトックスA (SERCABOT)

2026年10月1日 更新者:Centre Oscar Lambret

The goal of this phase II clinical trial is to study the effectiveness of a treatment with Serratus Plane Block (SPB) or Botox-A in comparison with capsaicin for the control of chronic neuropathic pain of post-mastectomy syndrom, that is not adequately managed by systemic treatment alone. The primary outcome will be the pain evaluation at 8 weeks.

123 patients with chronic neuropathic pain of post-mastectomy syndrom insufficiently relieved by systemic treatment alone will be recruited over 24 months at the Centre Oscar Lambret.

Patients will be randomly assigned to one of three treatment groups (41 patients per group):

Capsaicin Botulinum toxin A SPB

Patients will be followed for 24 weeks after the study treatment. The follow-up will include remote evaluation and 2 medical visits during which pain and quality of life will be assessed.

調査の概要

詳細な説明

SerCaBot is a randomized, open-label, phase II clinical trial designed to evaluate the efficacy of a treatment with Serratus Plane Block (SPB) or Botox-A compared to capsaicin for the control of chronic neuropathic pain of post-mastectomy syndrom, that is not adequately managed by systemic treatment alone.

123 patients with will be recruited over 24 months at the Centre Oscar Lambret.

This clinical trial will be proposed to patients with chronic neuropathic pain of post-mastectomy syndrome that is not adequately managed by systemic treatment alone.

After consent, an inclusion assessment will be carried out including clinical examination, anamnesis, pain assessment (questionnaires PCS, NPS, DN4, NPSI and collect of antalgic treatment) and evaluation of quality of life (questionnaire SF12) and depression (questionnaire HADS).

Patients will then be randomly assigned to one of three treatment groups : Capsaicin, Botox-A, SPB (41 patients per group). The randomization will be balanced 1:1:1, controlled by minimisation (with a random factor set at 0.8) for the distribution of the following factors:

  • Pain level at enrolment (continuous NPS)
  • Axillary dissection (yes vs. no)
  • Loco-regional adjuvant radiotherapy (yes vs. no)
  • Prior change of systemic treatment (yes vs. no)

The study treatment will be administered 1 to 2 weeks after randomization. Treatment will be stopped prematurely in the event of unacceptable toxicity or complication. In each group, a repeat of the treatment may be considered after 12 weeks if further pain control is required. In the SPB group, a repeat is also possible every 2 weeks.

Patients will be followed for 24 weeks after the study treatment. Follow-up will include:

  • 2 medical visits at 8 weeks and at 24 weeks including pain assessment (questionnaires NPS, NPSI, record of antalgic treatment), record of adverse events related to study treatment and assessment of quality of life (SF12 questionnaire) and depression (questionnaire HADS).
  • remote assessment at week-1, week-2, week-4 and week-6 including assessment of pain (questionnaires NPS, NPSI, record of antalgic treatment) and record of adverse events. This remote assessment will be repeated in case of repetition of treatment at week 12.

Patients will withdraw from the study after the 24 week medical visit. Early withdrawal will be possible in case of patient's decision of withdrawal, breast surgery during follow-up, or death.

研究の種類

介入

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Hauts-de-France
      • Lille、Hauts-de-France、フランス、59000
        • Centre Oscar Lambret

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

説明

Inclusion Criteria :

  1. Women aged ≥ 18 years;

  2. Unilateral breast cancer treated by total or partial mastectomy:

    • with sentinel lymph node technique (SLN) or axillary dissection;
    • with or without immediate reconstruction using a prosthesis;
    • associated or not with radiotherapy and/or chemotherapy;
  3. Presenting moderate to severe chronic neuropathic pain, defined by:

    • Numerical Pain Scale (NPS) ≥ 3 and DN4 ≥ 4,
    • on a localised aera ((≤ 240 cm²), at the surgical site, in the axillary hollow, or on the inner side of the ipsilateral arm,
    • between 3 and 9 months after breast surgery,
    • with indication of additional locoregional treatment in complement to a systemic treatment of chronic neuropathic pain, as recommended by the SFETD - French Society for the Study and Treatment of Pain (tricyclic antidepressants or IRSNA or gabapentinoid PLUS lidocaine patch, at the appropriate dosage) and implemented for at least 4 weeks;
  4. Patient affiliated with a health insurance plan;

  5. Patient informed and having consented to participate in the trial.

Exclusion Criteria :

  1. Ipsilateral breast cancer recurrence, regardless of the first treatment;

  2. History of breast or thoracic surgery prior to mastectomy with residual pain;

  3. Painful polyneuropathy related to chemotherapy requiring treatment;

  4. Ongoing or planned loco-regional adjuvant radiotherapy within the next 8 weeks;

  5. Treatment area not suitable for potential botulinum toxin type A treatment;

  6. Breast reconstruction using flap or lipomodelling;

  7. Indication for breast reconstruction within the next 8 weeks;

  8. Chronic pain of another etiology such as:

    • Neuropathic pain secondary to a neuroma (localized pain),
    • Radiodermatitis,
    • Phantom breast pain,
    • Lymphedema,
    • Complex regional pain syndrome,
    • Adhesive capsulitis,
    • Fibromyalgia;
  9. Hypersensitivity or allergy to anesthetics, capsaicin, naropein, clonidine hydrochloride, an amide-type local anesthetic, botulinum toxin type A, or any excipient contained in the preparations;

  10. Infection or inflammation at the injection site;

  11. Therapeutic/effective anticoagulation;

  12. Clinical signs or medical history leading to the diagnosis of:

    • Hemostasis disorder,
    • Local infection,
    • Severe renal insufficiency (creatinine clearance < 30 mL/min),
    • Thrombocytopenia < 50,000 platelets/mm3;
  13. Generalized muscle activity disorders (e.g., myasthenia, Lambert-Eaton syndrome);

  14. Heart rate lower than 60/minute;

  15. Severe bradyarrhythmia due to sick sinus syndrome or second or third-degree atrioventricular block;

  16. State of depression (HADS score ≥ 11);

  17. Other contraindication to any of the study treatments;

  18. Inability for the patient to follow the study schedule;

  19. Inability for the patient or the healthcare team to perform the treatment within 2 weeks;

  20. Pregnant or breastfeeding women, women who are able to conceive and who do not use a highly effective method of contraception during the trial and for at least 1 month after the end of treatment ;

  21. Patient under guardianship or curatorship.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Capsaicin 8% Patch (Control)

Participants in this arm will receive an 8% capsaicin patch in a single treatment session in addition to a systemic treatment that has been ongoing for at least 4 weeks. If pain persists, the capsaicin patch application may be repeated at 12 weeks.

One or two capsaicin patch (8%) are applied for 60 minutes to the site of neuropathic pain, in day-hospital. An oral, antalgic pre-medication may be done with one of the following medications (alone or association): paracetamol 1g, nefopam 30 mg, tramadol 100 mg, morphine 10mg, oxycodone 5mg. Capsaicin will be administered in addition to a systemic treatment that has been ongoing for at least 4 weeks. If pain persists, the capsaicin patch application may be repeated at 12 weeks.

他の名前:
  • Qutenza®
実験的:Serratus Plane Block (SPB)

Participants in this arm will undergo a Serratus Plane Block (SPB), a local anesthetic injection administered by a trained anesthesiologist, in addition to a systemic treatment that has been ongoing for at least 4 weeks. The SPB can be repeated every two weeks up to a maximum of four sessions within the initial 8-week period if pain persists. A repeat treatment may be considered at 12 weeks if further pain control is needed. This intervention aims to provide extended pain relief for neuropathic pain in post-mastectomy patients

The Serratus Plane Block (SPB) is a nerve block performed by a trained anesthesiologist to provide localized pain relief. It involves the injection of a local anesthetic: Maximum 150 mg naropeine combined with 150 μg clonidine hydrochloride into the serratus anterior plane under ultrasound guidance. An anesthesiologist will perform the procedure in a post-interventional recovery room, with light sedation.The SBP will be carried out in addition to a systemic treatment that has been ongoing for at least 4 weeks. The SPB may be repeated every two weeks up to four times in the initial 8-week period, with an additional repeat at 12 weeks if pain control remains insufficient.

他の名前:
  • SPB
実験的:Botulinum Toxin A (Botox-A) Injection

This arm involves administration of Botulinum Toxin A (Botox-A) at the site of pain, in addition to a systemic treatment that has been ongoing for at least 4 weeks. If pain remains unresolved, the injection may be repeated at 12 weeks. Botox-A is used here as a local, long-lasting analgesic intervention aimed at reducing chronic neuropathic pain in patients post-mastectomy.

Botulinum Toxin A (Botox-A) is injected into the affected area, with a total of 300 units administered across up to 60 injection sites. An anesthesiologist will perform the procedure in a post-interventional recovery room, with light sedation. This intervention will be carried out in addition to a systemic treatment that has been ongoing for at least 4 weeks, and is aimed at providing prolonged pain relief for post-mastectomy neuropathic pain. Light sedation is provided, and injections may be repeated at 12 weeks if necessary.

他の名前:
  • ボトックス
  • ボトックス-A

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Pain assessment using Numerical Pain Scale (END)
時間枠:8 weeks after treatment initiation, or the closest measurement within +/- 1 week if the 8-week data is missing.

The primary outcome measure is pain assessed by self-evaluation using the Numerical Pain Scale (END) ranging from 0 (no pain) to 10 (worst pain imaginable) at rest, evaluated 8 weeks after treatment (or 9 weeks after randomization if treatment was not performed). The patient's self-assessment reflects individual treatment efficacy. In case of treatment interruption due to immediate intolerance or technical issues, the baseline END will be considered for the primary analysis.

8 weeks after treatment initiation, or the closest measurement within +/- 1 week if the 8-week data is missing.

二次結果の測定

結果測定
メジャーの説明
時間枠
Success of Pain Control
時間枠:Assessed at 8 weeks post-treatment.

Defined as a reduction in pain of 3 points or more on the Numerical Pain Scale (END) at 8 weeks, with failure indicated in other cases.

Assessed at 8 weeks post-treatment.
Evolution of Pain Scores
時間枠:Assessed at multiple time points: 1, 2, 4, 6, 8, and 24 weeks.

Change in pain levels as self-reported by the patient using the END at 1, 2, 4, 6, 8, and 24 weeks after treatment (and at 13, 14, 16, and 18 weeks if treatment is repeated at 12 weeks).

Assessed at multiple time points: 1, 2, 4, 6, 8, and 24 weeks.
Neuropathic Component Evaluation
時間枠:Assessed at multiple time points: 1, 2, 4, 6, 8, and 24 weeks.

Change in neuropathic symptoms assessed via the Neuropathic Pain Symptom Inventory (NPSI) at 1, 2, 4, 6, 8, and 24 weeks after treatment (and at 13, 14, 16, and 18 weeks if treatment is repeated at 12 weeks).

Assessed at multiple time points: 1, 2, 4, 6, 8, and 24 weeks.
Early Treatment Failure
時間枠:Assessed at 7 and 14 days post-treatment

Early failure of local analgesic treatment defined by failure to perform the procedure (due to intolerance or technical issues) or failure to control pain as evaluated at 7 and 14 days post-procedure.

Assessed at 7 and 14 days post-treatment
Modification of introduction of New Analgesic Treatment
時間枠:Assessed at multiple time points: 1, 2, 4, 6, 8, and 24 weeks.

Documentation of any change in systemic treatement or introduction of new analgesic treatments (e.g., antiepileptics, antidepressants, opioids), with dosages collected at 1, 2, 4, 6, 8, and 24 weeks after treatment (and at 13, 14, 16, and 18 weeks if treatment is repeated).

Assessed at multiple time points: 1, 2, 4, 6, 8, and 24 weeks.
Adverse Events
時間枠:From study treatment to 24-weeks follow-up

Monitoring of adverse events possibly related to the treatment (capsaicin, botulinum toxin type A, or SBP block) during and after the local procedure, graded according to NCI-CTCAE v5.0.

From study treatment to 24-weeks follow-up
HADS Scale Evaluation
時間枠:Assessed at baseline, 8 weeks, and 24 weeks.

Assessment of anxiety and depression using the Hospital Anxiety and Depression Scale (HADS) at baseline, 8 weeks, and 24 weeks.

Assessed at baseline, 8 weeks, and 24 weeks.
Quality of Life Assessment
時間枠:Assessed at baseline, 8 weeks, and 24 weeks.

Evaluation of health-related quality of life using the SF12 scale at baseline, 8 weeks, and 24 weeks.

Assessed at baseline, 8 weeks, and 24 weeks.
Patient General Impression of Change (PGIC)
時間枠:Assessed at 8 weeks and 24 weeks

Self-assessment of change in condition from 1 (no change or worse) to 7 (considerable improvement) measured at 8 weeks and 24 weeks.

Assessed at 8 weeks and 24 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Didier DELBROUCK, Anesthesiologist、Centre Oscar Lambret

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年6月10日

一次修了 (実際)

2026年9月22日

研究の完了 (実際)

2026年9月22日

試験登録日

最初に提出

2025年1月29日

QC基準を満たした最初の提出物

2025年1月29日

最初の投稿 (実際)

2025年2月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月6日

QC基準を満たした最後の更新が送信されました

2026年10月1日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する